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Abstract
Background: Up-regulation of angiotensin II (AngII) occurs in cardiac diseases, such as congestive heart failure,
cardiac hypertrophy, myocardial ischemia and atrial fibrillation, which represent major health problems. Evidence
from in vivo studies suggests that the level of Apolipoprotein-J (ApoJ) is also elevated but plays a protective role in
cardiovascular disease. This study aimed to evaluate the protective effects of ApoJ against cytotoxicity of AngII in
neonatal rat ventricular cells (NRVCs).
Methods and results: In culture, NRVCs were damaged by exposure to AngII, and ApoJ overexpression using an
adenovirus vector significantly reduced the AngII-induced cell injury. ApoJ also prevented AngII from augmenting
Nox2/gp91phox expression. The reactive oxygen species (ROS) scavenger, Mn(III)TBAP, showed similar results of
attenuating AngII-induced cell damage. Furthermore, ApoJ overexpression increased phosphorylation of Akt, and
the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 diminished the antioxidant effects of ApoJ, and
prevented the protective effect of ApoJ against the cytotoxicity of AngII. Moreover, upregulation of nuclear factor
κB (NF-κB) p65 expression and phosphorylation of p38 mitogen-activated protein kinase (MAPK) mediated by AngII
in cultured NRVCs were significantly inhibited by overexpression of ApoJ. The p38 MAPK inhibitor SB203580 and
the NF-κB inhibitor PDTC protected NRVCs from injury caused by AngII.
Conclusions: ApoJ serves as a cytoprotective protein in NRVCs against cytotoxicity of AngII through the PI3K-Akt-
ROS and MAPK/ NF-κB pathways.
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Background
Apolipoprotein-J (ApoJ), also known as Clusterin, is a
multifunctional glycoprotein widely present in tissues
and body fluids. It has been implicated in such diverse
processes as sperm maturation, regulation of complement
activation, programmed cell death, tissue remodeling and
lipid transport. Expression of ApoJ is upregulated in acute
myocardial infarction, atherosclerosis, myocarditis, oxida-
tive stress, inflammation and after injury in general.
Klock et al. [1] demonstrated that apoptotic processes
are responsible for increased ApoJ expression, and the
function of ApoJ has been proposed to limit tissue injury
and/or promote tissue remodeling [2].
The amyloid precursor protein (APP) is cleaved by β -
and γ-secretase to release the amyloidogenic β-amyloid
peptides (Aβ) and the APP intracellular domain (AICD).
It has been believed that Aβ and AICD are involved in
the onset and progression of Alzheimer’s disease (AD).
AICD has been shown to potentiate endoplasmic
reticulum (ER) stress-induced apoptosis, and knockdown
of ApoJ mimicks the effect of AICD, suggesting that
ApoJ exerts a prosurvival function against ER stress-
mediated cell death [3]. Schwarz et al. [4] reported that
ApoJ has cytoprotective and anti-inflammatory proper-
ties, by interacting with diverse substrates, and they
demonstrated that ApoJ could inactivate C5b-9 comple-
ment complexes and reduce the cytotoxic effects of
modified LDL on cells. ApoJ overexpression using an
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adenovirus vector was shown to inhibit vascular smooth
muscle cells migration, adhesion and proliferation and
to be beneficial to endothelial cells in injured blood ves-
sels [5]. Blockage of secreted ApoJ by a monoclonal anti-
body resulted in increased apoptosis of neuroblastoma
cells exposed to the chemotherapeutic drug doxorubicin,
and its expression was required for resistance to apop-
totic cell death induced by the chemotherapeutic drug
doxorubicin [6]. In the heart, ApoJ was shown to exert
protective effects on ischemically-challenged H9c2 cells
and isolated adult ventricular rat cardiomyocytes [7]. In
addition, ApoJ-deficient but not wild-type mice were
found to exhibit impairment of cardiac function and se-
vere myocardial scarring. In general, activation of ApoJ
may play an important role in reducing apoptosis in nor-
mal and diseased cells.
Renin-angiotensin system (RAS) activation is known
to contribute to increased angiotensin II (AngII) levels,
thus leading to vascular damage, inflammation, oxidative
stress and atherosclerosis [8–10]. This study aimed to
determine whether ApoJ overexpression provides cardio-
protection against AngII-induced injury and to explore
the mechanisms by which ApoJ exerts its protective
effects.
Results
ApoJ overexpression attenuates cell injury induced by
AngII
To determine whether ApoJ exerts beneficial effects on
cardiomyocytes against AngII, ApoJ expression was
achieved by infection with recombinant adenovirus in
NRVCs. ApoJ expression was markedly increased in the
Ad-ApoJ-infected NRVCs but not in control adenovirus-
infected cells as confirmed by Western blot analysis with
an anti-rat ApoJ antibody (Fig. 1a). We then determined
the effect of ApoJ in AngII-induced cell injury, and
0.1 μM AngII was added into the adenovirus-infected
NRVCs 36 h after infection. ApoJ overexpression con-
ferred a significant resistance to cell death induced by
AngII, compared with the control adenovirus-infected
cells when exposed to AngII for 24 h. As shown in
Fig. 1b, expression of cleaved caspase-3 was enhanced by
AngII, and ApoJ overexpression markedly attenuated it.
Similar results were observed in the MTT assay, which
showed that AngII markedly decreased cell viability, and
ApoJ overexpression significantly prevented the decrease
in viability during exposure to AngII (Fig. 1c). Further-
more, the percentage of apoptotic cardiomyocytes which
increased after AngII administration was markedly re-
duced by ApoJ overexpression (Fig. 1c). These results
suggest that increased ApoJ expression plays a critical
role in protecting cardiomyocytes from cell death in-
duced by apoptotic agents. Next, we investigated which
downstream effectors of AngII [phosphatidylinositol-3-
kinase-Akt (PI3K/Akt), reactive oxygen species (ROS),
mitogen-activated protein kinase (MAPK) p38 or nu-
clear factor kB (NF-kB) p65] mediate apoptosis and
might be depressed by ApoJ to prevent AngII-induced
apoptosis. We used a PI3K-Akt inhibitor [2-(4-morpholi-
nyl)-8-phenyl-4 H-1-benzopyran-4-one, LY294002],
ROS scavenger [Mn(III)TABP], MAPKp38 inhibitor
(SB203580) or NF-κB p65 inhibitor (pyrrolidine dithiocar-
bamate, PDTC) in the presence of AngII. As shown in
Fig. 1e, Mn(III)TBAP, SB203580 and PDTC significantly
reduced the percent of apoptotic cells induced by AngII,
while LY294002 further increased cell apoptosis. These
results indicate that AngII mediates apoptosis through
MAPK38, NF-kB, and ROS, and PI3K/Akt is a potential
locus where ApoJ could act to ameliorate AngII-stimulated
apoptosis.
Phosphatidylinositol-3-kinase contributes to the
anti-apoptotic effect of ApoJ
In order to determine if ApoJ exerts protection on
NRVCs by reducing ROS production, we tested Nox2/
gp91phox expression. As shown in Fig. 2a, ApoJ overex-
pression markedly prevented AngII from stimulating the
Nox2/gp91phox expression, as compared with the con-
trol adenovirus-infected cells when exposed to AngII for
24 h. To define this putative signaling pathway, we
added the inhibitor of PI3K-Akt, LY294002, to NRVCs.
When LY294002 was added to the ApoJ-overexpressing
cells, it abrogated the effect of ApoJ on Nox2/gp91phox
expression (Fig. 2b). These results emphasize the in-
volvement of the PI3K-Akt pathway in the ApoJ-
mediated inhibition of AngII-induced ROS production
in NRVCs. Since the suppression of ROS production in
response to ApoJ was found to depend on the PI3K-Akt
pathway, we next inquired whether ApoJ treatment of
NRVCs would result in elevated phosphorylation of Akt.
As depicted in Fig. 2c, Akt phosphorylation increased
after exposure to AngII, and ApoJ overexpression further
significantly stimulated its expression. We also inves-
tigated if PI3K-Akt inhibitor (LY294002) affects the
ability of ApoJ to protect NRVC from AngII-induced
apopoptic injury. As shown in Fig. 2d, cell apoptosis
caused by AngII was significantly decreased by ApoJ
overexpression, while LY294002 significantly reduced
the ability of ApoJ to protect against AngII-induced
cell injury.
ApoJ prevents MAPK and NF-κB activation
To investigate whether the anti-apoptotic pathway
employed by ApoJ involves MAPK p38 and NF-κB p65,
we analyzed their expression levels. As shown in Fig. 3a,
results of the Western blots demonstrated that AngII
induced a significant increase of phosphorylated p38 pro-
tein, and this increase was abolished by ApoJ. Addition of
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exogenous AngII significantly increased NF-κB expres-
sion as compared to control adenovirus-infected cells,
and the increased phosphorylation of NF-κB p65 was
also significantly attenuated by ApoJ (Fig. 3b). These
results indicated that ApoJ protects NRVCs from
apoptosis via the MAPK/ NF-κB pathway initiated by
AngII.
Discussion
This study provides the first experimental evidence
showing that ApoJ attenuates AngII-induced apoptosis
in NRVCs. Furthermore, this study demonstrates that
the cytoprotection of ApoJ against AngII may be medi-
ated through activation of the PI3k-Akt pathway, thus
suppressing ROS production, and through inhibiting the
MAPK/NF-κB pathway.
ApoJ is associated with subclasses of plasma high
density lipoproteins (HDL), and elevated levels of HDL
have been inversely correlated with the risk of coronary
heart disease, suggesting that the protective effect
exerted by ApoJ is related to HDL. ApoJ is a circulating
glycoprotein, which can be induced by injury, such as
Alzheimer’s disease, atherosclerosis and myocardial in-
farction [11, 12]. In addition, ApoJ not only has been as-
sociated with apoptotic cell death but also demonstrated
to be expressed in apoptosis-resistant cells [13] and re-
quired for cell survival [14–17].
Previous studies have reported that ApoJ participates
in lipid transport, apoptosis regulation, protection of cel-
lular membranes and promotion of cell-cell interactions
[12]. The serum level of ApoJ level was found to be sig-
nificantly increased in type II diabetes patients and in
Fig. 1 ApoJ overexpression by infection with recombinant adenovirus prevents AngII-induced apoptosis in NRVCs. a Apo J expression after
infection by recombinant adenovirus was determined by Western blot (n = 3/group). b Cleavage of caspase-3 was stimulated by AngII and
inhibited by ApoJ (n = 3/group). c Control and ApoJ-transduced NRVCs were incubated with AngII for 24 h, and then cell viability was
determined by MTT assay (n = 8/group). d Apoptosis of cardiomyocytes was determined by caspase-3/7 activity assay. Apoptosis of control adenovirus
infected NRVCs was significantly increased, while ApoJ-overexpressing NRVCs showed resistance to AngII-induced cell injury (n = 8/group). e LY294002,
Mn(III)TBAP, SB203580 and PDTC were pretreated in NRVCs for 1 h, and then the cells were incubated with AngII for 24 h. Cell apoptosis
was determined by caspase-3/7 activity assay (n = 8/group). **P < 0.01 versus control Ad/PBS group; ##P < 0.01 versus control Ad/AngII group, $P < 0.05
versus control Ad/AngII group
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patients with either a developing coronary heart disease
or myocardial infarction as compared to healthy individ-
uals, but its level showed no correlation with the num-
ber of vessels with documented atherosclerotic damage
[18, 19]. Given the significant elevated level of ApoJ that
occurs in injury processes, an increased ApoJ level may
be a strong indication of vascular damage. However,
other studies have reported the decrease of ApoJ level
after cardiac injury. For example, Cubedo et al. [20] ob-
served that the serum ApoJ level was markedly de-
creased after the onset of acute myocardial infarction
(AMI) compared with control patients and returned to
control levels between 72 and 96 h after hospital
admission. Considering the contradictory findings re-
garding ApoJ in cardiovascular disease, its benefit or det-
riment to the heart…….
In the last decade, multiple lines of evidence have sug-
gested that ApoJ is associated with cell apoptosis. Poula-
kou et al. [21] discovered that serum ApoJ levels are
positively associated with coronary artery disease. Meth-
oxyacetic acid (MAA) treatment has been demonstrated
to cause a localization of ApoJ to the cytoplasm, which
precluded apoptotic cell death [22]. Overexpression of
ApoJ was also shown to protect cells from apoptosis [15,
16], and blocking of ApoJ biosynthesis by antisense oli-
gonucleotides caused an increase in cellular apoptosis in
Fig. 2 ApoJ attenuates the increased ROS production via PI3K-Akt pathway induced by AngII. a Western blot analysis of Nox2/gp91phox
expression in NRVCs. Nox2/gp91phox expression was enhanced by AngII in control adenovirus-infected cells, while ApoJ-transduced
cells inhibited its expression (n = 3/group). b LY294002 was used to pretreat ApoJ-transduced NRVCs for 1 h, and then the control and
ApoJ-transduced NRVCs were incubated with AngII for 24 h. Nox2/gp91phox expression was determined by Western blot (n = 3/group).
c AngII increased pAkt expression in control infected NRVCs, and ApoJ further augmented its expression. d Cell apoptosis caused by
AngII increased in ApoJ-overexpressing cells treated with LY294002. *P < 0.05 versus control Ad/PBS group, **P < 0.01 versus control Ad/PBS group;
#P < 0.05 versus control Ad/AngII group, ##P < 0.01 versus control Ad/AngII group,$P < 0.05 versus ApoJ group
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vitro [17, 23]. Bailey et al. [24] demonstrated that ApoJ
could delay cell apoptosis in heat-stressed testes, while
other studies using ApoJ knockout mice showed that
ApoJ could limit the severity of induced auto-immune
autocarditis [25] and exacerbate brain injury after neo-
natal hypoxia-ischemia [26]. ApoJ has been proposed to
be an antioxidant agent capable of protecting cells from
apoptosis induced by ROS [17]. Pathology studies have
discovered that ApoJ is constitutively expressed in atrial
but not in ventricular myocytes in healthy adult mouse
and rat hearts, while myocardial injury markedly upregu-
lates the level of ApoJ in ventricular myocytes. The
current study aimed to determine if elevated ApoJ exerts
protective effects in cardiomyocytes against the cytotox-
icity of AngII. Therefore, we overexpressed ApoJ in
NRVCs to define this function and found that it pre-
vented AngII-induced cell damage by increasing cell
viability and decreasing cell apoptosis. In addition,
we also found that MAPKp38 inhibitor, NF-κB p65
inhibitor and ROS scavenger exerted effects on
apoptosis of NRVCs similar to that afforded by ApoJ,
while PI3K-Akt inhibitor worsened cell damage in the
presence of AngII, indicating that PI3K-Akt, MAPKp38,
NF-κB p65 and ROS may take part in the signals that
regulate the response of ApoJ to AngII-induced cell
damage.
Apoptosis is a complex process that occurs through
many pathways [27]. ROS are well demonstrated as
agents that cause cell apoptosis. AngII has been found
to enhance NADPH oxidase activity that leads to in-
creased ROS production, thus initiating a number of
pathological processes. In this study, we found that
adenovirus-mediated overexpression of ApoJ abrogated
the elevated ROS production induced by AngII, as deter-
mined by reduced Nox2/gp91phox expression in NRVCs.
These results suggest that changes in the downstream
ROS pathways may take part in the mechanisms of the
anti-apoptotic effects of ApoJ.
AngII receptors are G-protein coupled receptors,
AngII binds to AT1R to activate downstream signaling
molecules such as PI3K, and activation of PI3K leads to
Akt phosphorylation. The PI3K-Akt pathway is activated
in response to various stimuli, growth factors and
hormones. Once activated, Akt phosphorylates many
cytosolic and nuclear substrates that are involved in nu-
merous cellular responses, including promotion of cell
survival, control of cell cycle progression and regulation
of cell growth. ApoJ serves as a circulating glycoprotein,
might bind to AT1R to facilitate Akt phosphorylation in
NRVCs. In this study, we found that ApoJ overexpres-
sion markedly augmented pAkt expression. However, ad-
ministration of the specific PI3K inhibitor LY294002
significantly impaired the ability of the ApoJ-expressing
adenovirus from reducing AngII-stimulated expression
of Nox2/gp91phox. Thus, ApoJ may exert its suppressive
effects on Nox2/gp91phox expression via activating the
PI3K-Akt pathway.
Accumulating lines of evidence have demonstrated
that up-regulation of NF-κB plays a critical role in
physiological processes, including cell survival and pro-
liferation, and in inflammatory diseases such as athero-
sclerosis [28]. NF-κB proteins are found in many types
of cells and respond to various stimuli, such as cytokines
and bacterial or viral antigens [29–31]. Previous studies
have demonstrated that AngII could activate the NF-κB
pathway. Here, we investigated the potential effect of
Fig. 3 Effects of ApoJ on expression of p38 kinase and NF-κB p65 in NRVCs. a MAPK p38 expression in NRVCs. Phosphorylated MAPK p38
expression was enhanced by AngII in control infected cells, while ApoJ-transduced cells inhibited its expression (n = 3/group). b Western blot
analysis of NF-κB expression in NRVCs. NRVCs were infected with control or ApoJ-expressing adenovirus for 36 h and then incubated with
AngII for 24 h. Addition of AngII increased phosphorylated NF-κB expression, while ApoJ-transduced cells significantly decreased its expression
(n = 3/group). *P < 0.05 versus control Ad/PBS group; **P < 0.01 versus control Ad/PBS group, #P < 0.05 versus control Ad/AngII group, ##P < 0.01
versus control Ad/AngII group
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ApoJ on NF-κB activation and related signal transduc-
tion in NRVCs treated with AngII. We found admin-
istration of AngII activated NF-κB p65 expression,
and this NF-κB activation could be blocked by over-
expression of ApoJ.
MAPK p38 is also responsive to various stimuli and is
involved in regulation of cellular processes, such as pro-
liferation, cell survival and apoptosis [32]. We investi-
gated the potential effect of ApoJ on MAPK p38
activation in NRVCs treated with AngII, and we found
administration of AngII activated MAPK p38 expression,
and this MAPK p38 activation could also be blocked by
overexpression of ApoJ.
Conclusions
In conclusion, this study demonstrated the ability of
ApoJ to inhibit AngII-induced cell damage via activating
PI3K activity, thus reducing ROS production, and via
inhibition of the MAPK/NF-κB pathway (See Fig. 4
for an illustration of the signaling pathway of ApoJ
action in NRVCs). Although these results may not be
extrapolated directly to in vivo situations, this study
provides evidence of a possible mechanism by which ApoJ
exerts protection in NRVCs and may therefore provide a
link to the prevention of atherosclerotic risk.
Methods
Animals
Neonatal Sprague–Dawley (SD) rats were obtained from
the Department of Experimental Animals of Hebei Uni-
versity (Shijiazhuang, Hebei, China). The investigation
was approved by the Animal Care and Use Committee at
Bethune International Peace Hospital (Shijiazhuang, Hebei,
China). The experiment was carried out in accordance with
The Code of Ethics of the World Medical Association
(Declaration of Helsinki).
Myocyte isolation and cell culture
Single ventricular myocytes were obtained by enzymatic
dissociation using collagenase (type II) and pancreatin as
described elsewhere with some modifications. Ventricu-
lar myocardial tissue from neonatal SD rats (aged 1 d,
Hebei Medical University) were homogenized and disso-
ciated with collagenase II and pancreatin six times for
20 min each time. The first cell suspension was dis-
carded, while the rest of the cell suspensions were dis-
pensed with FBS and mixed together in 10-cm plates for
1.5 h, allowing enrichment for cardiomyocytes by differ-
ential adhesion. The supernatant was then plated onto a
new dish with DMEM containing 10 % FBS at 37 °C.
Adenoviral infection of NRVCs
The ApoJ-expressing adenovirus was generated using
pAD-ApoJ-IRES-EGFP adenoviral vector. Adenovirus
generated from pAD-IRES-EGFP was used as control,
the adenoviral vectors were synthesized using the
Gateway Cloning System (invitrogen). Isolated NRVCs
were infected with indicated adenoviruses at a multiplicity
of infection (MOI) of 200 with serum-free DMEM.
After 4 h, supernatants were removed and replaced
with DMEM containing 10 % FBS. After 36 h, super-
natants were removed, and NRVCs were given different
treatments.
3-(4,5-Di methylthiazol-2-y l)-2,5-diphenylt etrazolium
bromide (MTT) assay
Cell viability was estimated using the MTT assay (Sigma,
St. Louis, MO, USA). Cells (2 × 104 cells/ml) were cul-
tured in complete medium for 24 h on 96-well plates.
Fig. 4 Signaling pathway diagram of ApoJ action in NRVCs. 1) In control adenovirus-infected cells, AngII stimulates phosphorylation of MAPK and
Akt, which enables the activation of NF-κB and NADPH oxidase and consequently induction of apoptosis in NRVCs. 2) In NRVCs, p38 MAPK, NF-κB,
Akt and NADPH oxidase activated by AngII are blocked by overexpression of ApoJ
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The medium on the cell cultures was replaced by fresh
medium containing 0.5 % FBS, and then the cells were
given different treatments. After the treatments, 20 μL
of MTT at a concentration of 5 mg/ml was added, and
the cells were incubated for 4 h. Thereafter, the medium
was discarded, and 150 μl of DMSO was added for
10 min. The absorbance at 570 nm was recorded in each
well using an ELISA microplate reader. All assays were
performed in triplicate and repeated three times.
Caspase-3/7 activity assay
Apo-ONE Homogeneous Caspase-3/7 Assay (Promega,
Madison, WI, USA) was used to measure apoptosis in
NRVCs. Briefly, cells plated in 96-well plates at a density
of 104 cells/well were given different treatments, and
then 100 μl of Apo-ONE Homogeneous Caspase-3/7 Re-
agent was added to each well. The plate was incubated
for 1 h at room temperature using a plate shaker at
350 rpm. Subsequently, fluorescence was measured in a
fluorometer with excitation at 499 nm and emission at
521 nm. All assays were performed in triplicate and re-
peated three times.
Immunoblotting
After being rinsed in cold PBS three times, cells were
homogenized in RIPA buffer. The supernatant was then
centrifuged at 120,000 × g for 15 min at 4 °C. Samples
(10–20 mg) were run on SDS-PAGE gels, transferred to
PVDF filter membranes and Western blotted with
monoclonal antibodies against phosphor-Akt (Ser473)
(Cell Signaling Technology, Beverly, MA, USA), Nox2/
gp91phox (Abcam, Cambridge, MA, USA), Phospho-NF-
κB p65 (Ser536) (Cell Signaling Technology), Phospho-
p38 MAPK (Thr180/Tyr182) (Cell Signaling Technol-
ogy), cleaved caspase-3 (Asp175) (Cell Signaling Tech-
nology), ApoJ (EterLife, Birmingham, UK) and β-Actin
(Sigma). PVDF membranes were then incubated with
HRP-conjugated anti-rabbit immunoglobulin G antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
1 h. The blot was developed with an ECL-Plus chemilu-
minescence reagent kit and visualized with the UVP Bio-
Imaging System. Blot densities were analyzed using
Image J software.
Statistical analysis
All values in the text and figures are presented as the
mean ± SD of n independent experiments. All data
(except Western blot density) were subjected to ANOVA
followed by Bonferroni correction for post hoc tests.
Western blot densities were analyzed with the Kruskal-
Wallis test followed by Dunn post hoc tests. P < 0.05 was
considered statistically significant.
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